No-one should die of Histiocytosis

Our research programmes provide a beacon of hope for the many children and adults battling Histiocytosis, to ensure this research continues we ask you to pledge your support.

Langerhans Cell Histiocytosis - Children

Langerhans Cell Histiocytosis – Children

previously known as Histiocytosis X

Dif­fe­rent working groups ha­ve re­view­ed avail­able in­ter­na­tio­nal and na­tio­nal gui­de­lines and re­com­men­da­ti­ons for dia­gno­sis, tre­at­ment and fol­low-up of LCH. A syn­the­sis of this in­for­ma­ti­on was ge­ne­ra­ted and publis­hed af­ter ap­pro­val of ma­ny in­vol­ved spe­cia­lists and is available from the EURO-Histio-Net website linked in the following LCH pages.

·  Lan­ger­hans Cell His­tio­cy­to­sis (LCH) – Child­ren
Gui­de­lines for dia­gno­sis, cli­ni­cal work-up and tre­at­ment du­ring child­hood; Ver­si­on 1.1, March 2011

The Guidelines include:
· Me­thods and Pro­cess of de­ve­lop­ment
· Pur­po­se and Re­stric­tions
· Ge­ne­ral Con­s­ide­ra­ti­ons

· Dia­gno­sis

De­fi­ni­ti­ve dia­gno­sis of LCH re­qui­res clas­si­cal his­topa­tho­lo­gy con­fir­med by de­mons­tra­ti­on of CD1a or Lan­ge­rin (CD207) or by the ul­tra­struc­tu­ral pre­sence of Bir­beck gra­nu­les.

Bio­p­sy and His­to­lo­gi­cal Ex­ami­na­ti­on
Dia­gnostic Cri­te­ria

· Pre­tre­at­ment Cli­ni­cal Eva­lua­ti­on

The fol­lo­wing pa­ti­ent eva­lua­ti­on is re­com­men­ded on­ly for pa­ti­ents with de­fi­ni­te dia­gno­sis of LCH and for tho­se with pres­ump­ti­ve LCH in whom a bio­p­sy is de­fer­red for the re­a­sons men­tio­ned in the chap­ter Bio­p­sy / His­to­lo­gy. In all other ca­ses we suggest eit­her con­sul­ting the re­fer­ral cen­ter of your coun­try or sha­ring the his­to­lo­gi­cal sli­des with other re­fe­rence or spe­cia­li­zed cen­ters:
Re­com­men­ded Eva­lua­ti­on in Every Ca­se
Spe­ci­fic Cli­ni­cal Sce­na­ri­os and Re­com­men­ded Ad­di­tio­nal Tes­ting
De­fi­ni­ti­on of Or­gan In­vol­ve­ment
Head MRI in LCH Pa­ti­ents

· Cli­ni­cal Clas­si­fi­ca­ti­on
Tre­at­ment re­com­men­da­ti­ons are ba­sed on site and ex­ten­si­on of the di­sea­se which is why it is im­portant to dis­tin­gu­ish bet­ween sin­gle sys­tem LCH and mul­ti­sys­tem LCH.

· Dif­fe­ren­ti­al Dia­gno­sis
· Tre­at­ment

Whe­ne­ver pos­si­ble pa­ti­ents should be en­rol­led in on­go­ing cli­ni­cal tri­als and trea­ted ac­cor­ding to the pro­to­col. CHILD­REN who are not en­rol­led in a cli­ni­cal tri­al should be trea­ted ac­cor­ding to the gui­de­lines pre­sen­ted he­re. Due to the di­ver­si­ty of cli­ni­cal cour­se of LCH, even re­com­men­da­ti­ons which are es­ta­blis­hed as stan­dard of ca­re may need to be cri­ti­cal­ly ap­prai­sed in an in­di­vi­du­al ca­se. We sug­gest that you ne­ver he­si­ta­te to con­ta­ct LCH ex­perts in ca­se that the cli­ni­cal cour­se rai­ses ques­ti­ons or doubts.

Ma­nage­ment Al­go­rithms
Lo­cal The­ra­py or Care­ful Ob­ser­va­ti­on
Sys­te­mic The­ra­py
Tre­at­ment Op­ti­ons in Ca­se of Re­ac­tiva­ti­on

· Fol­low-up of LCH pa­ti­ents

Ge­ne­ral Con­s­ide­ra­ti­ons; Dia­be­tes in­si­pi­dus; Hor­mo­ne De­fi­ci­en­cies; Or­tho­pa­edic Se­que­lae; Pro­blems with Ears, Oral Tis­sue and Jaw; Neu­ro­lo­gi­cal Se­que­lae; Da­ma­ge of Lung and Li­ver
Mo­ni­to­ring for Per­ma­nent Con­se­quen­ces
Fol­low-up – Re­qui­red Tests and Fre­quen­cy
Ma­li­gnan­cies As­so­cia­ted with Lan­ger­hans Cell His­tio­cy­to­sis

Our thanks to all of our Histio Partners for their input to these pages.


Your support is vital to ensure that we can continue to deliver our Research and Information Programs. Thank you.